Segment Information

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Segment Information

Segment Information

The Company manages its operations as a single segment focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Biohaven's Chief Executive Officer (“CEO”), as the Company's chief operating decision maker, manages and allocates resources at a consolidated level.

The CEO uses net loss that is also reported on the condensed consolidated statement of operations as net loss to assess performance and decide how to allocate resources. The measure of segment assets is reported on the condensed consolidated balance sheet as total consolidated assets. Expenditures for the addition of long-lived assets are reported on the condensed consolidated statements of cash flows as purchases of property and equipment.

Additional information about segment profit or loss and significant segment expenses is as follows:

	Three Months Ended March 31,
	2025		2024
Direct R&D program expense
BHV-4157 (Troriluzole)	$	13,788	$	17,087
BHV-2000 (Taldefgrobep Alfa)	6,184		11,128
BHV-7000 & BHV-7010 (Kv7)	31,573		24,803
BHV-2100 (TRPM3 Antagonist)	16,748		4,620
BHV-8000 (TYK2/JAK1)	4,373		4,249
BHV-1300 (IgG Degrader)	8,621		9,225
BHV-1310 (IgG Degrader)	1,074		3,261
BHV-1400 (IgA Degrader)	4,860		4,092
BHV-1600 (β1-AR AAB Degrader)	3,003		815
BHV-1510 (Trop2)	4,490		19,586
BHV-1530 (FGFR3)	3,176		—
Other R&D program expense	511		(241)
Preclinical research programs R&D Expense	25,535		11,863
R&D personnel expense (excluding share-based compensation)(1)	21,138		19,314
R&D Share-based compensation expense	35,233		21,291
G&A personnel expense (excluding share-based compensation)(1)	6,474		6,389
G&A Share-based compensation expense	17,829		13,586
Other segment items (2)	16,951		12,172
Non-operating (income) expense	(493)		(4,305)
Provision for income taxes	609		569
Segment net loss	221,677		179,504
Reconciliation of profit or loss
Adjustments and reconciling items	—		—
Consolidated net loss	$	221,677	$	179,504

(1)    Personnel expense includes employee payroll, bonus, and employee benefits for medical care, retirement, insurances and other.

(2)    Other segment items included in Segment net loss include unallocated non-program R&D expense, legal, accounting and other professional service fees, rent and utilities expense, depreciation, and other corporate expenses.